Multiple Sclerosis (MS)
67
16
20
28
Key Insights
Highlights
Success Rate
82% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
9.0%
6 terminated out of 67 trials
82.4%
-4.2% vs benchmark
9%
6 trials in Phase 3/4
36%
10 of 28 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 28 completed trials
Clinical Trials (67)
Comparing the Safety and Benefit of Natalizumab (Tysabri®) At-home Infusion vs At-hospital Infusion in Multiple Sclerosis
Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis
Assessment of the Quality of Life of Multiple Sclerosis Patients Treated With Ofatumumab in Real-life in France
A Palliative Care Model Impact on Knowledge and Attitudes
A Study on the Safety and Tolerability of Universal STAR-T Cell Therapy for Multiple Sclerosis.
Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden
Prevalence of Periodontitis in Egyptian Multiple Sclerosis Patients.
Serious Game Rehabilitation and Brain Plasticity in MS
Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy
Spinal Cord Lesion Detection in Multiple Sclerosis Using Novel MRI Sequences
Effect of Music Therapy on Pain in People With Multiple Sclerosis
MRI-Based Lesion Differentiation in Older Patients With Multiple Sclerosis
A Study of C-CAR168 in the Treatment of Central Nervous System Autoimmune Diseases Refractory to Standard Therapy
The Effect of Aerobic Exercise on an Elliptical Trainer Versus a Treadmill, in People With Multiple Sclerosis
Escalation vs. Induction Therapy Strategy in Patients With Early-Onset MS After Age 50
Multimodal Imaging Signatures of the Biological Mechanisms Underlying Neurodegeneration in Multiple Sclerosis
A Phase I Double Blind Study of Metformin Acting on Endogenous Neural Progenitor Cells in Children and Young Adults With Multiple Sclerosis
Vista Protein Expression of Monocyte and T Cell Subsets in Multiple Sclerosis and Its Clinical Correlation
COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders